TOLVAPTAN and THIRST

Overview

THIRST is the #5 most commonly reported adverse reaction for TOLVAPTAN, manufactured by Otsuka America Pharmaceutical, Inc.. There are 775 FDA adverse event reports linking TOLVAPTAN to THIRST. This represents approximately 3.2% of all 24,584 adverse event reports for this drug.

Patients taking TOLVAPTAN who experience thirst should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

THIRST is moderately reported among TOLVAPTAN users, representing a notable but not dominant share of adverse events.

Other Side Effects of TOLVAPTAN

In addition to thirst, the following adverse reactions have been reported for TOLVAPTAN:

• DEATH — 973 reports
• OFF LABEL USE — 814 reports
• RENAL IMPAIRMENT — 804 reports
• CARDIAC FAILURE — 785 reports
• PRODUCT DOSE OMISSION ISSUE — 522 reports
• PRODUCT USE IN UNAPPROVED INDICATION — 487 reports
• WRONG TECHNIQUE IN PRODUCT USAGE PROCESS — 480 reports
• UNDERDOSE — 477 reports
• DEHYDRATION — 449 reports
• BLOOD CREATININE INCREASED — 422 reports

Does TOLVAPTAN cause THIRST?

THIRST has been reported as an adverse event in 775 FDA reports for TOLVAPTAN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is THIRST with TOLVAPTAN?

THIRST accounts for approximately 3.2% of all adverse event reports for TOLVAPTAN, making it a notable side effect.

What should I do if I experience THIRST while taking TOLVAPTAN?

If you experience thirst while taking TOLVAPTAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages